Skip to main content
PRLD logo

Prelude Therapeutics Incorporated

PRLDNASDAQHealthcareBiotechnology

$3.32Today:- (-)1Y +153.44%

As of Oct 15, 2026 close

Market cap
$326.65M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.16$6.83
Volume (live)
-
Avg. volume (3M)
484.05K

Prelude Therapeutics Incorporated (PRLD) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Prelude Therapeutics Incorporated had return on equity of -99.5% (down from -69.0%), debt-to-equity of 0.26 (up from 0.14), a current ratio of 1.99 (down from 5.30) and return on assets of -40.7% (down from -38.5%). A current ratio of 1.99 means current assets exceed current liabilities.

Prelude Therapeutics Incorporated Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income StatementBalance SheetCash FlowRatios
Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio19.6813.82----
P/B Ratio3.480.741.361.472.0214.29
Price/Tangible Book3.480.741.361.472.0214.29
Enterprise Value Ratios
EV/Revenue16.63-----
Profitability & Returns
Return on Equity (ROE)-99.45%-69.01%-56.33%-47.97%-44.85%-49.67%
Return on Assets (ROA)-40.74%-38.54%-33.19%-29.38%-26.89%-29.92%
Return on Capital Employed (ROCE)-116.90%-93.20%-51.70%-62.10%-39.80%-27.70%
Leverage & Solvency Ratios
Debt/Equity0.260.140.070.010.01-
Liquidity Ratios
Current Ratio1.995.3010.799.4215.3719.41
Quick Ratio1.955.2110.679.2915.1719.19
Efficiency Ratios
Asset Turnover0.080.03----
Yield & Distribution Ratios
Earnings Yield-41.64%-131.47%-37.74%-40.16%-19.35%-1.88%
FCF Yield-23.59%-107.15%-34.25%-30.18%-14.87%-1.54%
Buyback Yield-1.52%-25.60%-27.41%-2.87%-269.03%-647.86%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Prelude Therapeutics Incorporated Financial Ratios

What is Prelude Therapeutics Incorporated's return on equity?

Prelude Therapeutics Incorporated's return on equity (ROE) was -99.5% for fiscal 2025 (period ended Dec 31, 2025). It was -69.0% a year earlier.

What is Prelude Therapeutics Incorporated's debt-to-equity ratio?

Prelude Therapeutics Incorporated's debt-to-equity ratio was 0.26 for fiscal 2025 (period ended Dec 31, 2025). It was 0.14 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition